This parameter was developed by the Joint Task Force on Practice Parameters,
representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the …

The implementation of treatment guidelines for atopic dermatitis is challenging, in part
because of different guidance documents being used by different groups of specialists and …

Guidelines/Outcomes Task Force: Abby Van Voorhees, MD, Chair Task Force, Mark A.
Bechtel, MD, Boni E. Elewski, MD, Steven R. Feldman, MD, Cindy Francyn Hoffman, MD …

Atopic dermatitis (AD) is a chronic, remitting-relapsing inflammatory dermatitis often
managed by a multidisciplinary group of providers including allergists, dermatologists, and …

abstract Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus
as a primary lesion, which is frequently encountered in clinical practice. Skin barrier …

Atopic dermatitis is an important component of the atopic diathesis. It not only frequently
accompanies allergic respiratory disease but often is the first manifestation of allergic …

Atopic dermatitis is an important and chronic skin condition that has recently been the
subject of enormous volumes of basic science, clinical, and epidemiologic research. This …

These parameters were developed by the Joint Task Force on Practice Parameters,
representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the …

Atopic dermatitis (AD), commonly known as eczema, is a chronic, pruritic inflammatory skin
disease associated with a profound physical and psychosocial burden, which can contribute …

Background Clinical signs are a core outcome domain for atopic dermatitis (AD) trials. The
current lack of standardization of outcome measures in AD trials hampers evidence-based …